Indeed, inhibitors of EGFR and another EGFR family member Her2, including Erlotinib, Lapatinib, Cetuximab, and Gefitinib, are the most successful options in current clinical treatment of different human cancers, As expected however, the development of de novo resistance has been observed in clinic after long-term use of these medicines, suggesting the existence of bypass mechanisms within tumor cells [11]. The gene discussed is EGFR; the disease is cancer.